{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:35:20Z","timestamp":1793954120388,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vaccine.2020.05.081","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T08:06:38Z","timestamp":1592381198000},"page":"5313-5323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1\/2 trial"],"prefix":"10.1016","volume":"38","author":[{"given":"Jakob P.","family":"Cramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Htay Htay","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-7874","authenticated-orcid":false,"given":"Stella","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"S\u00e1ez-Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.05.081_b0005","unstructured":"Global Polio Eradication Initiative. Global eradication of wild poliovirus type 2 declared. http:\/\/polioeradication.org\/news-post\/global-eradication-of-wild-poliovirus-type-2-declared\/ Accessed 20 March 2020."},{"key":"10.1016\/j.vaccine.2020.05.081_b0010","unstructured":"WHO. Two out of three wild poliovirus strains eradicated: Global eradication of wild poliovirus type 3 declared on World Polio Day - 24 October 2019. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/two-out-of-three-wild-poliovirus-strains-eradicated Accessed 20 March 2020."},{"key":"10.1016\/j.vaccine.2020.05.081_b0015","unstructured":"Global Polio Eradication Initiative. Polio this week as of 18 March 2020. http:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/ Accessed 20 March 2020."},{"key":"10.1016\/j.vaccine.2020.05.081_b0020","unstructured":"WHO. What is vaccine-derived polio? https:\/\/www.who.int\/features\/qa\/64\/en\/ Accessed 24 November 2019."},{"key":"10.1016\/j.vaccine.2020.05.081_b0025","unstructured":"SAGE Polio Working Group Report. Proposed policy for a switch from tOPV to bOPV globally. April 10, 2012."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.05.081_b0030","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1093\/infdis\/jiu128","article-title":"Affordable inactivated poliovirus vaccine: strategies and progress","volume":"210","author":"Okayasu","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.081_b0035","unstructured":"WHO SAGE. GAPIII Containment Certification Scheme, October 2016. http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/10\/CCS.pdf Accessed 20 March 2020."},{"key":"10.1016\/j.vaccine.2020.05.081_b0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.biologicals.2016.08.005","article-title":"Development of inactivated poliovirus vaccine from Sabin strains: A progress report","volume":"44","author":"Okayasu","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2020.05.081_b0045","doi-asserted-by":"crossref","unstructured":"Bakker WA, Thomassen YE, Van\u2019t Oever AG, Westdijk J, van Oijen MG, Sundermann LC, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011;29:7188\u201396.","DOI":"10.1016\/j.vaccine.2011.05.079"},{"key":"10.1016\/j.vaccine.2020.05.081_b0050","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1016\/j.vaccine.2013.09.021","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminium hydroxide: A phase 1 trial in healthy adults","volume":"31","author":"Verdijk","year":"2013","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2020.05.081_b0055","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2014.07.109","article-title":"Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba","volume":"32","author":"Resik","year":"2014","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.05.081_b0060","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial","volume":"29","author":"Chu","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.081_b0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2020.05.081_b0070","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 trial of a Sabin strain-based inactivated poliovirus vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J Infect Dis"},{"issue":"39","key":"10.1016\/j.vaccine.2020.05.081_b0075","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2014.07.029","article-title":"Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants","volume":"32","author":"Verdijk","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.05.081_b0080","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1080\/21645515.2018.1504538","article-title":"A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children","volume":"14","author":"Nakano","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2020.05.081_b0085","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/cid\/cix116","article-title":"Next generation inactivated poliovirus vaccine: the future has arrived","volume":"64","author":"Sutter","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2020.05.081_b0090","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jit155","article-title":"Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV)","volume":"208","author":"Okada","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.081_b0095","unstructured":"WHO Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). Replacement of Annex 2 of WHO Technical Report Series, No. 910. Available at: https:\/\/www.who.int\/biologicals\/vaccines\/Annex3_IPV_Recommendations_eng.pdf?ua=1 Accessed 20 March 2020."},{"key":"10.1016\/j.vaccine.2020.05.081_b0100","doi-asserted-by":"crossref","unstructured":"Weldon WC, Oberste MS, Pallansch MA. 2016. Standardized methods for detection of poliovirus antibodies. In: Methods in Molecular Biology; Martin J, ed. Humana Press, New York; vol. 1378, pp 145\u2013176.","DOI":"10.1007\/978-1-4939-3292-4_8"},{"issue":"8","key":"10.1016\/j.vaccine.2020.05.081_b0105","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","article-title":"Interval estimation for the difference between independent proportions: comparison of eleven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"issue":"10040","key":"10.1016\/j.vaccine.2020.05.081_b0110","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2020.05.081_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial","volume":"16","author":"S\u00e1ez-Llorens","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"5223","key":"10.1016\/j.vaccine.2020.05.081_b0120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/bmj.1.5223.404","article-title":"poliomyelitis immunization in infants in the presence of maternally transmitted antibody","volume":"1","author":"Perkins","year":"1961","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.081_b0125","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1136\/fn.83.1.F24","article-title":"Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth","volume":"83","author":"Linder","year":"2000","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.081_b0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/1096-9071(200104)63:4<305::AID-JMV1006>3.0.CO;2-U","article-title":"Age- and dose-interval-dependent antibody responses to inactivated poliovirus vaccine","volume":"63","author":"Sormunen","year":"2001","journal-title":"J Med Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.05.081_b0135","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/520546","article-title":"Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants","volume":"196","author":"Asturias","year":"2007","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.05.081_b0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1086\/508427","article-title":"Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico","volume":"195","author":"Dayan","year":"2007","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.05.081_b0145","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/cid\/ciy649","article-title":"Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the polio eradication endgame","volume":"67","author":"Gaensbauer","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.05.081_b0150","first-page":"1","article-title":"Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains","author":"Tang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.05.081_b0155","unstructured":"WHO. A guide to introducing inactivated polio vaccine: Based on the Polio Eradication & Endgame Strategic Plan 2013-2018. 2016. Available at: https:\/\/www.who.int\/immunization\/diseases\/poliomyelitis\/endgame_objective2\/inactivated_polio_vaccine\/Introduction_guide.pdf?ua=1 Accessed 20 March 2020."},{"issue":"9","key":"10.1016\/j.vaccine.2020.05.081_b0160","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"issue":"14","key":"10.1016\/j.vaccine.2020.05.081_b0165","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.vaccine.2019.02.034","article-title":"Polio vaccination coverage and seroprevalence of poliovirus antibodies after the introduction of inactivated poliovirus vaccines for routine immunization in Japan","volume":"37","author":"Satoh","year":"2019","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2020.05.081_b0170","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/cid\/cix110","article-title":"Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses","volume":"64","author":"Sun","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2020.05.081_b0175","first-page":"544","article-title":"Differences in antigenic structure of inactivated poliovaccines made from Sabin live-attenuated and wild-type poliovirus strains: impact on vaccine potency assays","volume":"221","author":"Crawt","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20307362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:47Z","timestamp":1759402067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20307362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":35,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0264410X20307362"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.081","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1\/2 trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Takeda Vaccines Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}